COVID19: FDA approves convalescence plasma treatment
The Food and Drugs Authority (FDA) has given approval to an investigational convalescent plasma collected from individuals who have recovered from COVID-19 for the treatment of critically ill COVID-19 patients.
Convalescent plasma (CP) is the term used for plasma that is removed from the blood of a person who has recovered from a disease, then transfused into a patient still battling it.
According to the Presidential Advisor on Health, Dr Anthony Nsiah-Asare, the approval was given on Monday, June 15.
It is expected that CP would be given to patients with severe COVID-19 to boost their ability to fight the virus.
It is also expected to help keep people who are moderately ill from becoming more ill and experiencing COVID-19 complications.